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ABSTRACT
Inhibitors of fatty acid amide hydrolase (FAAH) and anandamide
(AEA) uptake, which limit the degradation of endogenous canna-
binoids, have received interest as potential therapeutics for pain.
There is also evidence that endogenous cannabinoids mediate the
antinociceptive effects of opioids. Assays of pain-elicited and
pain-suppressed behavior have been used to differentiate the
effects of drugs that specifically alter nociception from drugs that
alter nociception caused by nonspecific effects such as catalepsy
or a general suppression of activity. Using such procedures, this
study examines the effects of the direct cannabinoid type 1 (CB1)
agonist ()-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-
4-(3-hydroxypropyl)cyclohexanol (CP55940), the FAAH inhibitor
cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester
(URB597), and the AEA uptake inhibitor N-(4-hydroxyphenyl)
arachidonylamide (AM404). Additional experiments examined
these compounds in combination with morphine. CP55940
produced antinociception in assays of pain-elicited, but not
pain-suppressed, behavior and disrupted responding in an as-
say of schedule-controlled behavior. URB597 and AM404 pro-
duced antinociception in assays of pain-elicited and pain-
suppressed behavior in which acetic acid was the noxious
stimulus, but had no effect on the hotplate and schedule-
controlled responding. CP55940 in combination with morphine
resulted in effects greater than those of morphine alone in
assays of pain-elicited and scheduled-controlled behavior but
not pain-suppressed behavior. URB597 in combination with
morphine resulted in enhanced morphine effects in assays of
pain-elicited and pain-suppressed behavior in which diluted
acetic acid was the noxious stimulus, but did not alter mor-
phine’s effects on the hotplate or schedule-controlled respond-
ing. These studies suggest that, compared with direct CB1
agonists, manipulations of endogenous cannabinoid signaling
have enhanced clinical potential; however, their effects depend
on the type of noxious stimulus.
Introduction
Agonists at cannabinoid type 1 (CB1) receptors produce
behavioral effects that include disruption of locomotor activ-
ity (Pascual et al., 2005; Smith et al., 2009), dysregulation of
food consumption (Järbe and DiPatrizio, 2005; Li et al.,
2006), interference with thermoregulation (Wang et al., 2008;
Diaz et al., 2009), and reinforcing effects (Justinova et al.,
2008; Negus and Rice, 2009). Research also implicates the
endogenous cannabinoid system in the mediation of pain
responses. Genetic (Cravatt et al., 2001; Lichtman et al.,
2004b) and pharmacological (Lichtman et al., 2004a; Costa et
al., 2010, 2006) inhibition of the activity of fatty acid amide
hydrolase (FAAH) or anandamide (AEA) uptake, both of
which limit the degradation of endogenous cannabinoids,
results in CB1-mediated antinociception. Because these ef-
fects are not accompanied by catalepsy, hypothermia, and
other effects that are associated with the administration of
direct CB1 agonists (Kathuria et al., 2003; Jayamanne et al.,
2006), there is interest in the clinical potential of endogenous
cannabinoid modulators as analgesics.
In preclinical pain assays, exogenous cannabinoid agonists
such as 9-tetrahydrocannabinol potentiate the effects of
morphine in the mouse tail-flick test (Cichewicz and McCar-
thy, 2003), the rat paw pressure test (Cox et al., 2007), and
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the rat formalin test (Finn et al., 2004). Such interactions are
of interest because of their therapeutic potential in the treat-
ment of pain (Welch, 2009), but enthusiasm is tempered by
the fact that CB1 agonists also potentiate other opioid effects
(Finn et al., 2004), including their reinforcing activity (Nor-
wood et al., 2003; Manzanedo et al., 2004; Solinas et al.,
2005).
Endogenous cannabinoids also modulate the antinocice-
ptive effects of opioids. For example, CB1 antagonists at-
tenuate morphine-induced antinociception in the hotplate,
writhing, and tail-flick tests (Pacheco et al., 2009; Miller et
al., 2011) and in models of hyperalgesia (da Fonseca Pa-
checo et al., 2008). Exogenously administered AEA in com-
bination with the FAAH inhibitor cyclohexylcarbamic acid
3-carbamoylbiphenyl-3-yl ester (URB597), N-(4-hydroxy-
phenyl)arachidonylamide (AM404) enhances the antinoci-
ceptive effects of morphine in the tail-flick test (Haller et
al., 2008), and methylarachidonoylflurophosphate, which
inhibits the degradation of the endogenous cannabinoids
AEA and 2-arachidonoylethanolamine, enhances the anti-
nociceptive effects of morphine in the tail-flick test and in
hyperalgesia models (da Fonseca Pacheco et al., 2008; Pa-
checo et al., 2009).
The vast majority of preclinical pain research uses behav-
ioral models that can be described as assays of pain-elicited
behavior. In these types of experiments, a noxious stimulus
(e.g., hotplate) evokes a behavioral response (e.g., licking of
the hindpaw). Assays of pain-suppressed behavior have been
used to complement these models and provide a more com-
plete characterization of candidate analgesics. In assays of
pain-suppressed behavior a noxious stimulus suppresses the
rate, frequency, or intensity of a particular behavior (Negus
et al., 2006). These assays can be used to differentiate the
effects of compounds that selectively alter responses to noci-
ceptive stimuli from compounds that produce nonspecific ef-
fects (e.g., general suppression of behavior). For example, the
clinical analgesic morphine attenuates nociceptive responses
and attenuates the suppression of behaviors by noxious stim-
uli (Stevenson et al., 2006). Compounds that attenuate pain-
elicited behavior and also restore behavior that has been
suppressed by pain may offer clinical advantages.
The primary purpose of the present study was to compare
the effects of the FAAH inhibitor, URB597, and the pur-
ported AEA uptake inhibitor, AM404, with a direct CB1
agonist, ()-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-
trans-4-(3-hydroxypropyl)cyclohexanol (CP55940), in two as-
says of pain-elicited behavior (hotplate assay and acetic acid-
elicited writhing) and two assays of pain-suppressed
behavior (acetic acid-suppressed feeding and wheel running).
Morphine, a clinically relevant analgesic, was examined for
comparison. In addition, the effects of morphine, URB597,
AM404, and CP55940 on food-maintained, schedule-con-
trolled behavior were examined to provide a measure of the
nonspecific, rate-decreasing effects of each drug. Based on
previous findings of cannabinoid/opioid interactions, the cur-
rent study also examined the effects of administration of a
FAAH inhibitor or an AEA uptake inhibitor in combination
with morphine. Previous studies have demonstrated that
CB1 agonists enhance a variety of opioid effects. Therefore,
assays of pain-elicited, pain-suppressed, and schedule-con-
trolled behavior may be useful in differentiating the effects of
combinations of these compounds with morphine.
Materials and Methods
Subjects
Male C57BL/6 mice purchased from The Jackson Laboratory (Bar
Harbor, ME) and bred in-house were approximately 12 weeks of age
at the beginning of testing. Mice were group-housed and had free
access to food and water except where specified by the experimental
protocols below. Lights were programmed on a 12-h light/dark cycle
with lights off at 7:00 AM. All experiments were conducted during
the dark cycle. Animal protocols were approved by the Institutional
Animal Care and Use Committee, and the methods were in accord
with the Guide for the Care and Use of Laboratory Animals (National
Research Council, 2011).
Experimental Procedures
Hotplate. Before testing, mice were habituated to the testing
room and handled on two separate occasions. During testing, the
mouse was placed onto the 56  0.1°C surface of the apparatus
(25.3  25.3 cm; Columbus Instruments, Columbus, OH), and the
latency to lick or flutter the hind paws or jump was recorded. A cutoff
time of 20 s was defined as the maximum trial duration.
Responses were measured 30 and 15 min before drug administra-
tion, and the latencies from these trials were averaged to yield one
baseline value. Separate groups of mice were used to test each drug
(groups of 8–10 mice per drug). During dose-effect determination for
morphine (0.32–32.0 mg/kg) and CP55940 (0.032–3.2 mg/kg), cumu-
lative doses were administered 30 min apart in half-log increments.
The doses and pretreatment times were selected based on previous
work in our laboratory. For URB597 (0.1–3.2 mg/kg) and AM404
(0.32–10.0 mg/kg) time courses were determined. Data shown are
from the 1-h time point (effects did not differ across time points). In
experiments examining the cannabinoids in combination with mor-
phine doses of CP55940, URB597, and AM404 that had no effect on
hotplate responses were administered 15 min before the commence-
ment of cumulative dosing of morphine as described above. In all
experiments, when CP55940, URB597, or AM404 produced a signif-
icant effect or produced changes in the morphine dose-effect curve
the effects of pretreatment with the CB1 antagonist 5-(4-chlorophe-
nyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-
carboxamide (SR141716A) were then determined. In this assay, a
dose of 3.0 mg/kg SR141716A, which does not alter hotplate latencies
when administered alone (Miller et al., 2011), was administered 75
min before testing. The effect of each treatment is expressed as the
percentage of the maximum possible effect (%MPE): [postdrug la-
tency (s)  baseline latency (s)]/[20  baseline latency (s)].
Acetic Acid-Induced Writhing. Mice were habituated to the
testing room and handling on two occasions before testing. Mice were
group-housed and had free access to food and water until 23 and 5 h
before testing, respectively. Mice were tested in groups of five to
eight animals per treatment, with each dose of a given drug tested by
using the same number of mice. Before drug testing, baseline assess-
ments were performed in which mice had 30-min access to 32% liquid
nutrition (vanilla flavor; CVS, Woonsocket, RI) on the day before
testing. During subsequent drug test days, mice were injected with
saline or morphine (0.1–3.2 mg/kg) 45 min before testing. CP55940
(0.01–0.32 mg/kg), URB597 (0.32–10.0 mg/kg), and AM404 (1.0–10.0
mg/kg) were injected 1 h before testing, and SR141716A was injected
75 min before testing. For drug combination testing with morphine
the pretreatment times above were maintained and combined with
doses of CP55940, URB597, and AM404 that had no effect on writh-
ing. Immediately before testing mice were injected with 0.56% acetic
acid or saline in control experiments. After this injection mice were
immediately placed into clean polycarbonate mouse cages (11.5 
7.5  5 inches; Allentown Inc., Allentown, NJ) containing dishes of
32% liquid nutrition (vanilla flavor; CVS). Their behavior was vid-
eotaped for 30 min for scoring at a later time. The effects of acetic
acid were examined once per animal. Writhes were operationally
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defined as an elongation of the body with simultaneous extension of
the hind limbs. The effect of each treatment is expressed as percent-
age of inhibition of writhing (% inhibition): [((writhes in saline-
treated mice  writhes in drug-treated mice)/writhes in saline-
treated mice)  100].
Acetic Acid-Suppressed Feeding. The data for the acetic acid-
suppressed feeding assay were collected in the same mice, during the
same session as the acetic acid-induced writhing assay. As a result,
the descriptions of the treatment of the mice in the previous section
apply.
Consumption of liquid nutrition was quantified by subtracting the
weight of the liquid-containing dishes after the session from the weight
obtained before the session. This value was divided by the animals’
weight, yielding grams of liquid consumed per gram of body weight.
In the event of spillage, the protocol was to discard those data, but
this did not occur during these experiments. The effect of each
treatment on pain-suppressed consumption is expressed as percent-
age of nonsuppressed consumption (% control): [(acetic acid-sup-
pressed consumption (g/g)/nonsuppressed consumption (g/g))  100].
Acetic Acid-Suppressed Wheel Running. At the start of the
experiment, mice were individually housed in polycarbonate cages
(14  10.5  5.5 inches; Tecniplast USA Inc., Exton, PA) containing
running wheels (ENV-044; MED Associates, St. Albans, VT). Testing
occurred after 2 weeks of habituation to handling and stabilization of
wheel-running behavior. Separate groups of mice were used to test
each drug (5–9 mice per drug). On the day before testing (control
session), mice were injected with saline followed 45 min later by a
second injection of saline after which wheel running (revolutions)
was recorded for 30 min. The next day (test session) mice were
injected with morphine (0.32–3.2 mg/kg), CP55940 (0.01–0.1 mg/kg),
URB597 (0.32–10.0 mg/kg), AM404 (1.0–10.0 mg/kg), SR141716A
(3.0 mg/kg), or vehicle, alone or in combination by using pretesting
injection times identical to those described for the writhing assay.
Immediately before the test, mice were injected with 0.56% acetic
acid or saline, and wheel running was recorded for 30 min. Acetic
acid-suppressed wheel running was examined up to four times in
each mouse with at least 1 week between exposures to acetic acid.
This schedule of exposure has no effect on wheel running beyond the
test day and does not produce long-term disruptions of other behav-
iors, such as feeding (Stevenson et al., 2006). The effect of each
treatment on pain-suppressed wheel running is expressed as per-
centage of nonsuppressed wheel running (% control): [(acetic acid-
suppressed running/nonsuppressed running)  100].
Schedule-Controlled Behavior. Mice were group-housed in
polycarbonate mouse cages (11.5  7.5  5 inches; Allentown Inc.)
and had free access to food and water except for the 2.5 h before test
days. Mice were habituated to the testing room and handling for 2
days before testing. Response rates in the assay of schedule-con-
trolled behavior were determined in standard mouse operant cham-
bers (8.5  7.0  5.0 inches; ENV-307W-CT; MED Associates).
During experimental sessions mice were placed into the darkened
chambers for 10 min. After this acclimation period, the ventilator fan
was activated, the left nose-poke hole was illuminated, and left nose-
poke responses were counted toward completion of a fixed ratio (FR)
response requirement (right nose pokes had no scheduled conse-
quences). After an initial training period, the FR value was increased
from 1 to the terminal ratio of 4, and completion of the FR resulted in
the light within the left nose-poke hole being turned off, access to a
liquid reinforcer (32% liquid nutrition; CVS), and activation of the
house light for 8 s. Once the reinforcer delivery period elapsed, the
dipper was lowered, the house light was turned off, and the left nose-
poke hole was illuminated, signaling the onset of the next response
period. Separate groups of mice were used to test each drug (6–7 mice
per drug). Testing occurred 5 days per week, and sessions ended after
30 min elapsed or when 100 reinforcers were earned.
Once response rates were stable, the effects of morphine (1.0–10.0
mg/kg; 45-min pretreatment), CP55940 (0.01–1.0 mg/kg; 1-h pre-
treatment), and URB597 (1.0–17.0 mg/kg; 1-h pretreatment) were
examined. After the determination of the effects of these drugs alone,
the mice did not receive drugs for 2 weeks before being redistributed
into separate groups to determine the effects of AM404 (1.0–17.0
mg/kg; 1-h pretreatment) and various drug combinations. Drug ef-
fects were assessed on Tuesdays and Fridays. Drug data are expressed
as a percentage of control response rates (% control): [(responses per
min on test day/responses per min on control day)  100].
Drugs
Morphine sulfate, URB597, and SR141716A were provided by the
National Institute on Drug Abuse (Bethesda, MD). AM404 was pur-
chased from Tocris Bioscience (Ellisville, MO), and CP55940 was
purchased from Sigma-Aldrich (St. Louis, MO). Acetic acid was pur-
chased from Thermo Fischer Scientific (Waltham, MA) and diluted in
0.9% saline for intraperitoneal administration (0.1 ml/10 g). All
drugs except morphine (administered in saline) were administered
in a vehicle of saline, ethanol, and emulpher in a ratio of 18:1:1.
Morphine, CP55940, URB597, AM404, and SR141715A were in-
jected subcutaneously at a volume of 0.1 ml/10 g.
Data Analysis
Data are expressed as mean ( S.E.M.) percentage of MPE, per-
centage of inhibition, percentage of control feeding, or percentage of
control wheel running, depending on the assay (see above). The dose
required to produce a 50% maximal effect (ED50) was derived by
using linear regression when possible, and differences in potency
were determined and expressed as a potency ratio with 95% confi-
dence limits. In instances in which determination of ED50 values was
not possible, one-way analysis of variance was used to determine
treatment effects. In these instances, comparisons were conducted by
using Dunnet’s test. The effects of pretreatment with SR141716A on
the effects of CP55940, URB597, and AM404 were analyzed with
unpaired t tests.
In experiments in which ED50 values could be determined isobo-
lographs or pseudo-isobolographs were constructed to determine
whether drug interactions were additive, supra-additive, or infra-
additive. In instances when the values obtained from drug combina-
tions did not deviate significantly from a diagonal line connecting the
ED50 of morphine and the drug with which it was combined (or a
vertical line arising from the ED50 value of morphine alone when the
ED50 of the combined drug could not be determined), the interaction
was defined as additive. When the ED50 value obtained from a drug
combination fell to the left or right of the line of additivity, the
interaction was supra-additive or infra-additive, respectively. In
these studies, deviation from the line of additivity was defined by
determining whether the error bars of the combination ED50 over-
lapped the error bars of the drug-alone error bars (Li et al., 2010). All
statistical analyses were conducted with an  level of significance set
at p  0.05.
Results
Morphine and CP55940 produced dose-dependent in-
creases in percentage of MPE in the hotplate with maximal
effects obtained at the highest doses tested, whereas URB597
and AM404 did not produce antinociception on the hotplate
(Fig. 1a). In contrast to the effects obtained on the hotplate,
morphine, CP55940, URB597, and AM404 all inhibited
writhing in the acetic acid writhing assay (Fig. 1b). Injection
of acetic acid that was preceded by saline or the cannabinoid
vehicle resulted in mean ( S.E.M.) writhes of 29.67 (2.96)
and 25.88 (2.72), respectively. Morphine, CP55940, and
URB597 all produced more than 75% inhibition of writhing.
At peak effect, morphine and CP5594 eliminated the writh-
ing response entirely, and URB597 produced a marked de-
crease in writhing [mean ( S.E.M.) writhes of 2.63 (1.10)].
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No dose of AM404 fully eliminated writhing, but doses of
1–10 mg/kg significantly inhibited the writhing response
(F4,35  22.88; p  0.05). At peak effect, AM404 decreased the
mean ( S.E.M.) number of writhes to 16.33 (3.87). The
maximal effects produced by CP55940, URB597, and AM404
in these assays were attenuated by 3.0 mg/kg of the canna-
binoid antagonist SR141716A (Table 1).
Pretreatment with a dose of CP55940 (0.1 mg/kg) that was
ineffective when administered alone on the hotplate pro-
duced a significant leftward shift in the morphine dose-
effect curve (Fig. 2; see Table 2 for ED50 values and potency
ratios), and this effect was attenuated by the cannabinoid
antagonist SR141716A. Isobolgraphic analyses suggest that
0.032 and 0.1 mg/kg CP55940 interacted with morphine in an
additive and supra-additive manner, respectively. Doses of
URB597 and AM404 that had no effect when administered
alone failed to alter morphine’s antinociceptive effects in the
hotplate.
Pretreatment with 0.01 mg/kg CP55940 and 0.32 mg/kg
URB597, neither of which was effective in the writhing assay
when administered alone, produced significant leftward
shifts in the morphine dose-effect curve (Fig. 3; see Table 2
for ED50 values and potency ratios), and isobolographic anal-
yses indicated that interactions between morphine and both
CP55940 and URB597 are additive. The effect of combined
administration of these compounds was attenuated by 3.0
mg/kg of the cannabinoid antagonist SR141716A. AM404 did
not alter morphine’s effects in this assay.
Injection of acetic acid resulted in a significant suppression
in feeding (t10  11.32; p  0.05) with mean consumption (
S.E.M.) of 0.01 (0.003) g/g body weight after acetic acid,
relative to control values of 0.11 (0.01) g/g body weight. As
shown in Fig. 4a, only URB597 attenuated the suppression of
feeding produced by an injection of acetic acid (F4,35  11.48;
p  0.05). The peak attenuation, after 10.0 mg/kg URB597,
resulted in mean percentage control consumption ( S.E.M.)
of 72.47 (11.90). This effect was antagonized by 3.0 mg/kg
SR141716A (Table 1). Although there was some indication
that morphine attenuated the suppression in feeding produce
by the injection of acetic acid, these effects were not statisti-
cally significant. URB597 at 3.2 mg/kg, a dose that attenu-
ated the suppression of feeding by acetic acid, and 3.0 mg/kg
SR141716A did not alter nonsuppressed feeding under these
conditions (Table 3).
Under control conditions, mean wheel-running revolutions
per min ( S.E.M.) were 1101 (210). Running was completely
eliminated (t14  4.04; p  0.05) after administration of
acetic acid. Figure 4b shows that URB597 (F4,35  4.03; p 
0.05), morphine (F4,34  4.82; p  0.05), and AM404 (F3,28 
Fig. 1. Effects of morphine, URB597, CP55940, and AM404 in the
hotplate (a) and writhing (b) assays. Abscissae, doses in milligrams/
kilograms. Ordinate in a, percentage of maximum possible effect.
Ordinate in b, percentage of inhibition of writhing. The hexagon and
diamond above V/S represent the effects of saline and the cannabinoid
vehicle, respectively.
TABLE 1
Mean (S.E.M.) effect of selected doses of CP55940, URB597, and AM404 alone and in combination with 3.0 mg/kg SR141716A
SR141716A significantly attenuated the effects of each drug in each assay (determined by unpaired by t tests with an  level of significance of 0.05).
Drug Alone 	 3.0 mg/kg SR141716A
Hotplate, %MPE
1.0 mg/kg CP55940 100 (0.00) 33.39 (8.30)
Acetic acid-elicited writhing, % inhibition
0.32 mg/kg CP55940 99.98 (0.02) 4.76 (15.57)
10.0 mg/kg URB597 90.00 (4.19) 13.02 (19.06)
10.0 mg/kg AM404 37.78 (14.74) 3.50 (3.06)
Acetic acid-suppressed feeding, % control
10.0 mg/kg URB597 72.48 (11.90) 5.58 (1.09)
Acetic acid-suppressed running, %
control
10.0 mg/kg URB597 54.08 (12.73) 9.94 (5.82)
10.0 mg/kg AM404 31.18 (9.87) 5.09 (2.73)
Schedule-controlled behavior, % control
0.1 mg/kg CP55940 1.06 (0.66) 62.61 (17.61)
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6.82; p  0.05), but not CP55940, significantly attenuated the
suppression of wheel running after an injection of acetic acid.
Although these drugs significantly attenuated the suppres-
sion of wheel running, the mean percentage of control run-
ning ( S.E.M.) obtained after morphine [maximum effect:
49.7 (17.1)], URB597 [maximum effect: 54.0 (12.7)], and
AM404 [maximum effect: 32.4 (9.79)] shows that none of the
compounds restored wheel running to control levels. In this
Fig. 2. Effects of morphine alone and in com-
bination with CP55940 (CP), URB597
(URB), and AM404 in the hotplate. a, c, and
e, dose-effect curves. Abscissae, doses of mor-
phine in milligrams/kilograms. Ordinates,
percentage of maximum possible effect. SR,
SR141716A. b, d, and f, isobolographs. Ab-
scissae, morphine ED50 in milligrams/kilo-
grams. Ordinates, CP5594, URB597, or
AM404 ED50 in milligrams/kilograms. Sym-
bols above CP, URB, and AM404 show the
effects of each drug alone.
TABLE 2
ED50 (95% CL) values and potency ratios obtained from combined administration of morphine with CP55940, URB597, and AM404 in the hotplate
assay
Blank spaces indicate that these values could not be determined. Asterisks indicate a significant shift in the morphine dose-effect curve, defined as a potency ratio with 95%
confidence limits that do not include 1.
Hotplate Writhing
ED50 (95% CL) Potency Ratio (95% CL) ED50 (95% CL) Potency Ratio (95% CL)
URB597 1.30 (0.92–1.84)
AM404
CP55940 0.49 (0.30–0.81) 0.03 (0.01–0.08)
Morphine 9.03 (7.04–11.59) 0.42 (0.28–0.65)
	 0.032 mg/kg CP55940 9.83 (7.90–12.23) 1.09 (0.80–1.49)
	 0.1 mg/kg CP55940 2.60 (1.65–4.08) 3.56 (2.14–5.92)* 0.16 (0.09–0.29) 2.77 (1.62–4.82)*
	 0.32 mg/kg URB597 0.17 (0.10–0.28) 2.44 (1.49–4.02)*
	 1.0 mg/kg URB597 6.55 (4.94–8.69) 1.31 (0.93–1.85)
	 3.2 mg/kg URB597 7.67 (5.87–10.02) 1.17 (0.83–1.64)
	 10.0 mg/kg URB597 8.79 (6.62–11.67) 1.02 (0.72–1.45)
	 1.0 mg/kg AM404 0.38 (0.19–0.76) 1.12 (0.64–1.95)
	 3.2 mg/kg AM404 6.61 (4.77–9.16) 1.28 (0.89–1.85)
	 5.6 mg/kg AM404 5.92 (4.01–8.75) 1.41 (0.96–2.08)
	 10.0 mg/kg AM404 6.25 (4.76–8.22) 1.38 (0.99–1.94)
	 17.0 mg/kg AM404 8.87 (7.19–10.94) 1.03 (0.75–1.41)
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assay, the effects of 10 mg/kg URB597 and 10 mg/kg AM404
were antagonized by 3.0 mg/kg SR141716A (Table 1). Al-
though 1.0 mg/kg morphine, 10.0 mg/kg URB597, and 10.0
mg/kg AM404 attenuated the suppression of wheel running
by acetic acid, these treatments and 3.0 mg/kg SR141716A
had no effect on nonsuppressed running (Table 4).
Morphine [ED50 (95% CL)  4.36 (3.47–5.48)] and
CP55940 [0.05 (0.05–0.06)] dose-dependently decreased re-
sponse rates in the assay of schedule-controlled behavior,
whereas URB597 and AM404 had no effect on responding in
this assay (Fig. 4c). The cannabinoid antagonist SR141716A
attenuated the rate-decreasing effects of 0.1 mg/kg CP55940
(Table 1).
CP55940 and AM404 did not alter morphine’s effects on
pain-suppressed feeding (Fig. 5). Although morphine had no
effect on pain-suppressed feeding when administered alone,
when morphine was combined with an ineffective dose of
URB597 (0.32 mg/kg) suppression of feeding by acetic acid
injection was attenuated (F3,22  49.15; p  0.05), and this
effect was antagonized by 3.0 mg/kg SR141716A. Likewise,
although CP55940 and AM404 did not alter morphine’s ef-
fects in the wheel-running assay, when 0.32 mg/kg URB597,
which had no effect when administered alone, was adminis-
tered in combination with morphine the increase in wheel
running was greater than that obtained with morphine alone
(F1,46  6.53; p  0.05). This effect was attenuated by 3.0
mg/kg SR1411716A.
A dose of CP55940 (0.032 mg/kg) that had no effect when
administered alone produced a significant leftward shift in
the morphine dose-effect curve in the assay of schedule-
controlled behavior (Fig. 6) [ED50 (95% CL)  1.05 (0.81–
1.45)], yielding a potency ratio (95% CL) of 4.16 (3.01–5.75).
Isobolographic analysis suggests that this interaction was
additive. Pretreatment with the CB1 antagonist SR141616A
(3.0 mg/kg), which had no effect on response rates when
administered alone, attenuated the rate-decreasing effects of
the CP55940/morphine combination. URB597 and AM404
did not alter morphine’s rate-decreasing effects in this assay.
Discussion
Table 5 summarizes the primary findings of this study.
Specifically, the FAAH inhibitor URB597, the purported
AEA uptake inhibitor AM404, and morphine were the only
drugs to produce antinociception as operationally defined in
at least one assay of pain-elicited behavior and assays of
Fig. 3. Effects of morphine alone and in
combination with CP55940 (CP), URB597
(URB), and AM404 in the writhing assay.
a, c, and e, dose-effect curves. Abscissae,
doses of morphine in milligrams/kilograms.
Ordinates, percentage of maximum possi-
ble effect. SR, SR141716A. b, d, and f, isobo-
lographs. Abscissae, morphine ED50 in mil-
ligrams/kilograms. Ordinates, CP55940,
URB597 or AM404 ED50 in milligrams/ki-
lograms. Symbols above CP, URB, and
AM404 show the effects of each drug alone.
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pain-suppressed behavior. CP55940 was effective only in the
assays of pain-elicited behavior, and none of the drugs tested
here were effective in all of the assays. These experiments
also show that URB597 and AM404 did not disrupt food-
maintained operant behavior at any dose tested, including
those that produced antinociception, whereas morphine and
CP55940 dose-dependently decreased response rates in this
assay. Finally, although the combination of CP55940 and
morphine produced greater antinociceptive effects than mor-
phine alone in both assays of pain-elicited behavior, this
combination also enhanced rate-decreasing effects in the as-
say of schedule-controlled behavior. In contrast, the combi-
nation of URB597 and morphine resulted in enhanced anti-
nociceptive effects in the writhing assay and the two assays
of pain-suppressed behavior, but did not enhance rate-de-
creasing effects on schedule-controlled behavior.
Research has shown that pharmacological manipulations
that inhibit AEA degradation (Lichtman et al., 2004a; Kinsey et
al., 2009; Costa et al., 2010) or limit AEA uptake (Costa et al.,
2006) are efficacious in preclinical pain models. Furthermore,
the blockade of endocannabinoid degradation does not produce
many of the nonantinociceptive effects that are associated with
CB1 agonists, such as catalepsy and disruption of locomotor
activity (Cravatt et al., 2001; Moore et al., 2005; Russo et al.,
2007). The results of the present experiments are consistent
with these findings. First, the results obtained from the assays
of pain-suppressed behavior suggest that URB597 and, to a
lesser extent, AM404 produce antinociception at doses that do
not produce nonspecific, behavioral suppressant effects. Effec-
tive doses of these compounds did not produce nonspecific in-
creases in the behaviors measured by these models. In addition,
a range of doses of URB597 and AM404, including doses that
are effective in numerous pain models and have been shown to
increase AEA levels (Fegley et al., 2004, 2005), failed to de-
crease rates of schedule-controlled responding. In contrast, the
CB1 agonist CP55940 only produced maximum antinociception
at doses that also resulted in decreases in schedule-controlled
behavior.
The effects of URB597 and AM404 in these studies seem to
be CB1-mediated given their attenuation by the CB1 antag-
Fig. 4. Effects of morphine, URB597, CP55940, and AM404 on pain-
suppressed feeding (a), pain-suppressed wheel running (b), and schedule-
controlled behavior (c). Abscissae, doses in milligrams/kilograms. Ordi-
nate in a, percentage of control consumption. Ordinate in b, percentage of
control running. Ordinate in c, percentage of control response rate. The
hexagon and diamond above V/S represent the effects of saline and the
cannabinoid vehicle, respectively. Vehicle and drug data presented for
the feeding and running assays were collected in the presence of acetic
acid and are expressed as a percentage of vehicle data collected in the
absence of acetic acid.
TABLE 3
Liquid nutrition consumption (grams consumed/gram of body weight)
by control mice, mice receiving 0.56% acetic acid in the absence of drug
treatments, and mice receiving drug treatments in the absence of
acetic acid
Asterisk indicates a significant difference in consumption compared with animals






0 Saline 0.11 (0.01)
0.56% Saline 0.01 (0.003)*
0 3.0 mg/kg SR1417116A 0.10 (0.01)
0 3.2 mg/kg URB597 0.09 (0.01)




Wheel running (revolutions) by control mice, mice receiving 0.56%
acetic acid in the absence of drug treatments, and mice receiving drug
treatments in the absence of acetic acid
Asterisk indicates a significant difference in wheel running compared with animals






0 Saline 1101.75 (210.30)
0.56% Saline 0.00 (0.00)*
0 3.0 mg/kg SR1417116A 775.38 (178.04)
0 1.0 mg/kg morphine 998.63 (210.30)
0 10.0 mg/kg URB597 945.17 (242.83)
0 10.0 mg/kg AM404 961.00 (266.01)
0 0.32 mg/kg URB597 	 0.56 mg/kg
morphine
794.17 (104.56)
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onist SR141716A. This finding is consistent with a body of
literature suggesting that cannabinoid antinociception oc-
curs largely via activity at CB1 receptors, although a com-
plete description of the mechanisms that underlie these ef-
fects remains unidentified. There is evidence that disruption
of endogenous cannabinoid metabolism could produce effects
at other receptors such as CB2 (Booker et al., 2012) and
transient receptor potential cation channel subfamily V
member 1 (Howlett et al., 2002). In addition, inhibition of
FAAH enhances AEA levels and those of other fatty acid
amides (Clement et al., 2003), and, as a result, the mecha-
nisms that mediate the effects seen here warrant further
examination.
Previous studies have examined interactions between the
cannabinoid and opioid systems by administering CB1 ago-
nists in combination with morphine and have consistently
shown that CB1 agonists enhance the antinociceptive effects
of morphine (Smith and Martin, 1992; Welch and Stevens,
1992; Smith et al., 1994; Welch et al., 1995; Massi et al.,
2001). More recent studies using CB1 antagonists also pro-
vide evidence that endogenous cannabinoids mediate the an-
tinociceptive effects of morphine (da Fonseca Pacheco et al.,
2008; Pacheco et al., 2009; Miller et al., 2011). Moreover,
morphine’s antinociceptive effects are enhanced when AEA is
protected from metabolism (da Fonseca Pacheco et al., 2008;
Haller et al., 2008; Pacheco et al., 2009).
The present study demonstrates that the combination of an
ineffective dose of URB597 with morphine produced greater
antinociception than morphine alone in the writhing assay,
the pain-suppressed feeding assay, and the pain-suppressed
wheel-running assay. The CB1 antagonist SR141716A atten-
uated the effects of this combination, indicating a role for
CB1 receptors, but it should be noted that this antagonist
also attenuates the effects of URB597 alone (present study)
as well as those of morphine alone (Miller et al., 2011). Thus
SR141716A effects on URB597 and morphine may have con-
tributed to the attenuation of the effects of URB597 and
morphine in combination. URB597 did not alter morphine’s
effects in the hotplate assay or the assay of schedule-con-
trolled behavior. Because URB597 did not enhance mor-
phine’s effects on schedule-controlled behavior, it is unlikely
that the enhancement in morphine’s antinociceptive effects is
caused by an increase in its behavioral suppressant effects.
This is in contrast to the CB1 agonist CP55940, which en-
hanced morphine antinociception in both assays of pain-
elicited behavior (hotplate and writhing), but also enhanced
morphine’s rate-decreasing effects. Therefore, it is possible
that the differences in experimental outcomes for the direct
Fig. 5. Effects of morphine alone and in
combination with CP55940 (CP; a and b),
URB597 (URB; c and d), and AM404 (AM;
e and f) in the pain-suppressed feeding
assay (a, c, and e) and pain-suppressed
wheel-running assay (b, d, and f). Abscis-
sae, doses of morphine in milligrams/ki-
lograms. Ordinates in a, c, and e, percent-
age of control consumption. Ordinates in
b, d, and f, percentage of control running.
Symbols above CP, URB, and AM show
the effects of each drug alone. SR,
SR141716A.
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agonist and the FAAH inhibitor could be caused in part by
enhancement of morphine’s behavioral suppressant effects
by the former and a lack of behavioral suppression by the
latter.
Previous studies have demonstrated supra-additive inter-
actions between opioids and CB1 agonists, and the data
reported here for CP55940 and morphine in the hotplate
procedure support those findings. The current experiments
also indicate that combinations of morphine and CP55940
produce additive effects in the writhing and schedule-con-
trolled behavior assays. Taken together, these finding sug-
gest that CB1 agonists are not likely to enhance morphine’s
antinociceptive effects without also producing other un-
wanted effects and that there may be limited clinical utility
for cannabinoid agonist/morphine combinations. URB597
and morphine also interacted in an additive manner in the
preclinical pain assays, but in contrast to CP55940, there
was no enhancement of morphine’s rate-decreasing effects.
The underlying mechanisms of the differing behavioral
effects of URB597 and CP55940 are not entirely clear, but
there is evidence that tonic exposure to noxious stimuli ele-
vates endocannabinoid levels in regions associated with pain
processing (Mitrirattanakul et al., 2006; Agarwal et al.,
2007). Furthermore, the endogenous cannabinoid system
modulates a variety of CNS functions, and there is evidence
that certain neurotransmitter systems may be more sensitive
to endocannibinoid control than others (Adermark and
Lovinger, 2009). Relative to exogenous agonists, the effects of
drugs such as FAAH inhibitors, which enhance the activity of
endogenous ligands, are probably influenced to a large extent
Fig. 6. Effects of morphine alone and in
combination with CP55940 (CP),
URB597 (URB), and AM404 (AM) in the
assay of schedule-controlled behavior.
a, c, and e, dose-effect curves. Abscis-
sae, doses of morphine in milligrams/
kilograms. Ordinates, percentage of
control rate. b, d, and f, isobolographs.
Abscissae, morphine ED50 in milli-
grams/kilograms. Ordinates, CP5594,
URB597, or AM404 ED50 in milligrams/
kilograms. Symbols above CP, URB,
and AM show the effects of each drug
alone. SR, SR141716A.
TABLE 5
Summary of drug effects in all five assays
Yes and No indicate whether the drug produced antinociception in the pain assays. For the assay of schedule-controlled behavior, Yes and No indicate whether the drug
produced rate-decreasing effects. Arrows indicate that the combination of the compound with morphine produced effects that were greater than morphine alone.
Hotplate Writhing Feeding Running Schedule-Controlled Behavior
Morphine Yes Yes No Yes Yes
CP55940 Yes1 Yes1 No No Yes1
URB597 No Yes1 Yes1 Yes1 No
AM404 No Yes No Yes No
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by the role of endocannabinoids under basal conditions and
in response to environmental changes. Drugs such as
URB597 may enhance endocannabinoid levels in a manner
that reveals regional and/or temporal selectivity, and this
selectivity may explain the relative absence of other CNS
effects (e.g., locomotor effects, reinforcing effects) after ad-
ministration of these compounds compared with direct CB1
agonists. Such evidence is compelling, comparing the effects
and potential clinical utility of cannabinoid agonists and
drugs that alter endogenous cannabinoid signaling, but other
variables warrant examination. For instance, CP55940 is a
full CB1 agonist whereas AEA is a partial CB1 agonist
(Pertwee et al., 2010), but the effects of lower-efficacy exog-
enous CB1 agonists have not been determined.
URB597 and AM404 resulted in antinociception only when
acetic acid was used as a noxious stimulus. A peripherally
acting FAAH inhibitor, 3-carbamoyl-6-hydroxy-[1,1-biphenyl]-
3-yl cyclohexylcarbamate (URB937), produces CB1-dependent
antinociception in a variety of pain models that involve tonic
exposure to noxious stimuli, including acetic acid (Clapper et
al., 2010). In addition, peripheral FAAH inhibition produces
CB1-dependent suppression of dorsal horn responses to forma-
lin injection in the hind paw of rats (Clapper et al., 2010).
However, like the results obtained with URB597 and AM404 in
the present study, URB937 was not effective on the hotplate.
Although URB597 and AM404 are not restricted to the periph-
ery, taken together, these data suggest that elevations of anan-
damide in the periphery are sufficient to produce antinocicep-
tion in assays of pain-elicited and pain-suppressed behavior
depending on the noxious stimulus used in a particular assay.
Therefore, examination of peripherally restricted inhibitors of
endogenous cannabinoid degradation and noxious stimuli other
than intraperitoneal acetic acid, in assays of pain-elicited and
pain-suppressed behavior, may provide valuable information
about the role of the endogenous cannabinoid system in pain
processing.
It should be noted that, although the assays of pain-elicited
and pain-suppressed behavior were useful in differentiating
the effects of CP55940 from URB597 and AM404, the com-
bination of drug effects observed across the assays of pain-
suppressed behavior in this study were not entirely predic-
tive of clinical utility. Specifically, morphine, an opioid that is
widely used clinically, did not significantly attenuate the
suppression of feeding by acetic acid. Others have demon-
strated the effectiveness of morphine in assays of pain-sup-
pressed feeding (Stevenson et al., 2006) as well as other
behaviors such as wheel running (present study), locomotor
activity (Stevenson et al., 2009), and intracranial self-stimu-
lation (Pereira Do Carmo et al., 2009). Thus, a growing body
of literature supports the potential for assays of pain-sup-
pressed behavior to complement traditional preclinical pain
assays.
Taken together, these experiments demonstrate that ad-
ministration of URB597 and, to a lesser extent, AM404,
result in CB1-mediated antinociception in assays in which
the operational definition of antinociception is a decrease in
pain-elicited behaviors as well as in assays in which antino-
ciception is defined as a decrease in the suppression of be-
havior by noxious stimuli. In addition, these experiments
suggest that combinations of URB597 and morphine result in
enhanced antinociceptive effects without recruiting nonspe-
cific effects. These studies, together with other recent find-
ings, suggest that compounds that enhance endogenous can-
nabinoid signaling may have potential as therapeutics,
whereas CNS effects associated with direct CB1 agonists
seem to pose a significant obstacle to their clinical utility.
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